60
Participants
Start Date
March 30, 2024
Primary Completion Date
March 30, 2025
Study Completion Date
March 30, 2025
Labetalol
it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent
Nitroglycerine
a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses
Nifedipine
dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive
Sohag University
OTHER